Biomea Fusion

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companies lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

On <a href="https://twitter.com/OptionsAction/status/1403468873211564033">CNBC&#39;s &quot;Options Action,&quot;</a> Tony Zhang said there is a potential downside in Okta Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/okta#NASDAQ">OKTA</a>).
The stock is trading in a very wide range between $210 and $290, it has underperformed its sector and recently it recorded some lower highs. It also had a strong last week, which Zhang sees as an opportunity to look for some short exposure. He expects the stock to test its support at $210.
To make a bearish bet, Zhang wants to buy the August $220/$190 put spread for a total cost of $8.60. The trade breaks even at $211.40 or 6.62% below the closing price on Friday. If the stock drops at least 16%, to $190 or lower, the trade is going to reach its maximal profit of $21.40.

Short Ideas

Options

Markets

Media

Trading Ideas

OKTA

Tony Zhang's Okta Options Trade

In the gambling universe, a sharp refers to a person or group that has a good track record betting on games.
Sometimes, sharps will sell their picks to other bettors to tail.
Unlike recreational gamblers, sharps take betting very seriously and often bet large sums of money on single bets.
Now, recreational sports bettors in certain states can go to sites such as&nbsp;Draftkings Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dkng#NASDAQ">DKNG</a>) or Penn National Gaming&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/penn#NASDAQ">PENN</a>) Barstool Sportsbook, making sports gambling even more popular.&nbsp;
Tricks From Sharp &mdash;&nbsp;Making Sense of the Books: Oddsmakers have a great understanding of how the public likes to bet. For instance, because most sports fans like watching an exciting, high-scoring game, bettors almost always favor the over. This allows oddsmakers to set the over/under higher than it should be because they know the public can&rsquo;t help but take the over and root for a lot of points, goals or runs.
Watch Out For Moving Lines: Odds for games will often change from when the lines open&nbsp;to game time.
For example, the Los Angeles Lakers could be listed as 10-point favorites when betting opens on the game. But, if it comes out the day before the game that Lebron James is hurt and going to miss the game, the line could be affected.
It&rsquo;s important for bettors to watch out for moving lines&nbsp;and understand why the lines are moving.
Reverse Line Movement: <a href="https://www.thesportsgeek.com/blog/tips-to-help-you-bet-like-a-sharp/">Many sites allow you</a> to see what the &quot;public bet&quot;&nbsp;is on. This means that if 80% of people are betting on the Lakers against the Phoenix Suns and the Lakers are 10-point favorites, you will be able to see it.
It would be expected&nbsp;if 80% of the public are taking one side, the line would move in that direction and&nbsp;the Lakers would become 11-point favorites.
But this is not always what happens, sometimes the line will move in the opposite direction.
This is because even though 80% of public tickets are coming in on the Lakers, large bets could be placed on the Suns. The percentage of public bet does not equal the total amount of money being bet on one side.
Any time there is reverse line movement, it&#39;s because large bets, or whales, are taking the other side.
(Photo: <a href="https://unsplash.com/@introspectivedsgn">Erick McLean</a> via <a href="https://unsplash.com/">Unsplash</a>)

Education

Sports

General

DKNG

PENN

Professional Gamblers And 'Sharps' Use These Tricks: Why Don't More Sports Bettors?

<ul>
<li>Benzinga has examined the prospects for many investor <a href="https://www.benzinga.com/trading-ideas">favorite stocks</a> over the past week. </li>
<li>The past week&#39;s bullish calls included the e-commerce leader, a top biotech and the airlines.</li>
<li>The iPhone maker, the top cryptocurrency and a COVID-19 vaccine maker were among the bearish calls seen.</li>
</ul>
The big three U.S. indexes offered mixed signals last week, with the Nasdaq ending almost 2% higher, the S&amp;P 500 up fractionally and the Dow Jones industrials lagging with almost a 1% retreat.
The S&amp;P 500 did manage to <a href="https://www.benzinga.com/news/earnings/21/06/21529911/chewy-earnings-beat-expectations-and-travel-industry-now-in-focus-ahead-of-summer">eke out a new record</a> high last week, but overall, Wall Street seemed to be in wait and see mode, with speculation that the reopening cycle may have already peaked, former drivers <a href="https://www.benzinga.com/news/earnings/21/06/21493474/gamestop-earnings-expected-later-today-with-chewy-seen-reporting-tomorrow">tech and financials still sputtering</a> and ahead of the coming week&#39;s FOMC meeting. The <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21512345/stock-market-volume-has-been-subdued-outside-of-meme-stocks-like-clov-and-wwe">Consumer Price Index</a> came in hotter than expected, though the muted market reaction suggests inflation fears may have already been priced in.
Bucking the low volume trend last week were the meme stocks, which offered retail investors another wild ride. In addition, a notable FDA drug approval gave <a href="https://www.benzinga.com/markets/binary-options/21/06/21474477/pharma-biotech-stocks-start-week-with-a-bang-after-biogens-alzheimers-approval">biotech stocks a bit of a boost</a>. Still, some investment firms are anticipating a <a href="https://www.benzinga.com/news/earnings/21/06/21452867/on-the-doorstep-s-p-500-begins-week-close-to-record-highs-with-inflation-data-up-next">muted second half of the year</a> for the markets.
The week also saw the <a href="https://www.benzinga.com/news/21/06/21510932/keystone-xl-pipeline-shut-down-what-investors-should-know-about-owner-tc-energy" target="_blank">Keystone Pipeline shut down</a>, a <a href="https://www.benzinga.com/news/21/06/21475029/what-to-know-about-the-glitch-that-crashed-the-internet-today">major internet outage</a>, the <a href="https://www.benzinga.com/topic/wwdc" target="_blank">Worldwide Developers Conference</a> and an agreement on a <a href="https://www.benzinga.com/news/21/06/21446570/g7-agrees-to-minimum-15-corporate-tax-reuters">global corporate tax</a>.
Through it all, Benzinga continued to examine the prospects for many of the stocks most popular with investors. Here are a few of this past week&#39;s most bullish and bearish posts that are worth another look.
<h3>The Bulls</h3>
Although Amazon.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) has lagged other FAANG names over the last year, its growth momentum will continue. So says the investment strategist featured in Adam Eckert&#39;s &quot;<a href="https://www.benzinga.com/trading-ideas/long-ideas/21/06/21498912/stephanie-link-sees-continued-growth-momentum-for-amazon-stock">Stephanie Link Sees Continued Growth Momentum For Amazon Stock</a>.&quot;
Be sure to check out <a href="https://www.benzinga.com/news/21/06/21480549/amazon-sidewalk-what-investors-device-owners-should-know">Amazon Sidewalk: What Investors, Device Owners Should Know</a> as well.
In &quot;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21475260/5-biogen-analysts-on-fda-approval-of-alzheimers-drug-aduhelm-broad-label-pricing">5 Biogen Analysts On FDA Approval Of Alzheimer&#39;s Drug Aduhelm, Broad Label, Pricing</a>,&quot; Shanthi Rexaline reveals why some see a strong drug launch ahead for Biogen Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biib#NASDAQ">BIIB</a>).
Also read <a href="https://www.benzinga.com/general/biotech/21/06/21497288/3-major-trends-in-biotech-that-are-revolutionizing-medical-research">3 Major Trends in Biotech that are Revolutionizing Medical Research</a>.
&quot;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21514443/mkm-partners-initiates-coverage-on-airline-sector-names-delta-top-pick">MKM Partners Initiates Coverage On Airline Sector, Names Delta Top Pick</a>&quot; by Wayne Duggan examines expectations for Delta Air Lines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dal#NYSE">DAL</a>) and its peers as Americans take to the sky again.
Phil Hall&#39;s &quot;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21476936/ubs-analyst-upgrades-target-what-you-need-to-know">UBS Analyst Upgrades Target: What You Need To Know</a>&quot; discusses why Target Corporation&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgt#NYSE">TGT</a>) valuation is modest compared to its peers and there is more to come from the retailer this year.
For more on Target, see <a href="https://www.benzinga.com/news/21/06/21493637/target-hikes-quarterly-dividend-by-32">Target Hikes Quarterly Dividend by 32%</a>.
In Priya Nigam&#39;s &quot;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21513160/jpmorgan-upgrades-ups-after-recent-sell-off">JPMorgan Upgrades UPS After Recent Sell-Off</a>,&quot; discover why the United Parcel Service, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ups#NYSE">UPS</a>) investor day impressed one top analyst, who now sees an &quot;attractive entry point&quot; for the shares.
<h3>The Bears</h3>
&quot;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21485632/apple-will-find-it-hard-to-recover-from-fallout-over-app-store-policies-says-bill-g">Apple Will Find It Hard To Recover From Fallout Over App Store Policies, Says Bill Gurley</a>&quot; by Madhukumar Warrier explores how Apple Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) could have avoided the mess in which it finds itself.
On the other hand, check out <a href="https://www.benzinga.com/markets/options/21/06/21515456/apple-options-traders-pile-in-despite-market-uncertainty">Apple Options Traders Pile In Despite Market Uncertainty</a>.
In Adrian Zmudzinski&#39;s &quot;<a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21515065/bitcoin-might-be-entering-a-bearish-market-jpmorgan-analysts-suggest">Bitcoin Might Be Entering A Bearish Market, JPMorgan Analysts Suggest</a>,&quot; find out what signal one top analyst sees as pointing to a bear market for Bitcoin (CRYPTO: BTC) despite its recent price movements.
See <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21475197/is-the-game-over-for-bitcoin-why-crypto-influencers-think-it-could-get-worse">Is The Game Over For Bitcoin? Why Crypto Influencers Think &#39;It Could Get Worse&#39;</a> for more low expectations for this top cryptocurrency.
Wayne Duggan&#39;s &quot;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21475069/2-reasons-why-tesla-has-become-an-ev-stock-laggard">2 Reasons Why Tesla Has Become An EV Stock Laggard</a>&quot; shows that there has been a clear shift in investor sentiment toward Tesla, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>)relative to other electric vehicle stocks.
<a href="https://www.benzinga.com/trading-ideas/long-ideas/21/06/21528545/teslas-stock-steers-into-triangle-and-looks-to-choose-direction">Tesla&#39;s Stock Steers Into Triangle And Looks To Choose Direction</a> offers a look at the chart at the end of a week full of good news and bad for the EV leader.
The Moderna, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) stock run could be over as COVID-19 fades from the headlines, according to &quot;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21512375/why-bofa-is-bearish-on-moderna-despite-covid-19-vaccine-success">Why BofA Is Bearish On Moderna Despite COVID-19 Vaccine Success</a>&quot; by Shanthi Rexaline.
In &quot;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21512630/bofa-downgrades-clover-health-after-100-stock-surge">BofA Downgrades Clover Health After 100% Stock Surge</a>,&quot; Priya Nigam looks at how recent price moves have overshadowed the prospects for meme stock Clover Health Investments Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clov#NASDAQ">CLOV</a>).
Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga">Benzinga</a> on Twitter.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Long Ideas

AAPL

AMZN

BIIB

CLOV

MRNA

TSLA

Benzinga's Bulls And Bears Of The Week: Apple, Amazon, Biogen, Bitcoin, Tesla And More

Thailand has banned all meme tokens, fan tokens, exchange tokens and non-fungible tokens (NFTs), the country&rsquo;s Securities and Exchange Commission said in a <a href="https://www.sec.or.th/TH/Pages/News_Detail.aspx?SECID=8991" style="text-decoration-line:none">statement</a> Friday.
What Happened: The Thai SEC didn&rsquo;t specifically mention the high-profile cryptocurrency Dogecoin (DOGE), which is expected to fall under the category of meme tokens, CoinDesk, which first <a href="https://www.coindesk.com/no-doge-allowed-thai-sec-bans-meme-fan-and-exchange-tokens-as-well-as-nfts" style="text-decoration-line:none">reported</a> the news, noted.
See Also: <a href="https://www.benzinga.com/money/how-to-buy-dogecoin-doge/" style="text-decoration-line:none">How to Buy Dogecoin (DOGE)</a>
Dogecoin, created as a joke in late 2013, is up 5456% in 2021, as of press time &mdash; the highest among the top 10 cryptocurrencies by market capitalization. The meme coin has found a major backer in Tesla Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) CEO Elon Musk.
The Thai regulator described meme cryptocurrencies as ones whose price is primarily driven by social indicators and have no clear objective or substance on their own.
Fan tokens representing ownership of voting rights or access to club-specific rewards and services are also now banned in Thailand, CoinDesk noted. An exception would be fan tokens used for goods and services like VIP experiences.
NFTs, another hot trend of 2021, also stand banned, alongside cryptocurrencies issued by exchange desks like Binance, Uniswap, and FTX for on-platform benefits.
Price Action: Dogecoin traded 1.7% lower at $0.3149 at press time on Sunday.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21504329/exclusive-dogecoin-co-creator-on-development-efforts-says-no-knock-on-elon-others-but-acti" style="text-decoration-line:none">Dogecoin Co-Creator On Development Efforts Says &#39;No Knock On Elon,&#39; Others But Actions Speak Louder Than Words</a>

News

$BTC

$DOGE

$ETH

Dogecoin Not Cute Enough For Thailand, Country Bans All Meme Coins, NFTs

On <a href="https://www.cnbc.com/video/2021/06/11/adobe-earnings-coming-up-and-heres-what-the-chartmaster-sees.html">CNBC&#39;s &quot;Options Action,&quot;</a> Carter Worth said he thinks Adobe Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adbe#NASDAQ">ADBE</a>) is solid and strong. The stock has returned where it was almost a year ago and it has just started to show relative outperformance to the S&amp;P 500. Worth noticed several technical patterns that suggest the stock has bottomed and he expects it to break out on the upside.
Mike Khouw wants to use options to make a bullish bet. With earnings coming up on June 17, short-term implied volatilities are elevated relative to the long-term implied volatilities so he wants to take advantage of that dynamic by buying the September $540 calls for $28.35 and selling the June $555 calls for $4.60. The trade would cost him $23.75, which is the maximum amount he can lose. If the stock trades sharply higher, above $555 the trade is going to underperform as the spread is only $15 wide.

ADBE

Carter Worth And Mike Khouw's Adobe Trade

On <a href="https://www.cnbc.com/video/2021/06/11/cramer-lightning-round-buy-spotify-at-these-levels.html">CNBC&#39;s &quot;Mad Money Lightning Round,&quot;</a> Jim Cramer said Restoration Hardware Holdings (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rh#NYSE">RH</a>) is just getting started and it goes higher.
Moody&#39;s Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mco#NYSE">MCO</a>) is a buy, said Cramer. He likes S&amp;P Global Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spgi#NYSE">SPGI</a>) better.
Cramer would hold NVIDIA Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) and he would buy more if it drops below $700.
Never bet against Eric Grubman, said Cramer. He is a buyer of his SPAC, Sports Entertainment Acquisition Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/seah#NYSE">SEAH</a>).
ChargePoint Holdings Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chpt#NYSE">CHPT</a>) is very good, but it has three other competitors Cramer analyzed. With that much competition, he feels it&#39;s difficult to own the stock.
At these levels, you want to buy Spotify Technology SA (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spot#NYSE">SPOT</a>), said Cramer.

Small Cap

CHPT

NVDA

SEAH

SPGI

SPOT

Cramer Gives His Opinion On Nvidia, Spotify And More

The Euro 2020 is set to begin June 11 with the Group Stage and run through July 11. The games will be aired on ESPN and EPSN+, both units of&nbsp;Walt Disney Co&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dis#NYSE">DIS</a>).
Ahead of the quadrennial soccer tournament featuring the top teams in Europe, Benzinga is providing group betting previews. Group D Betting Odds from Draftkings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dkng#NASDAQ">DKNG</a>) are:
<ul>
<li>England to win group -250, to finish top two in group -1250</li>
<li>Croatia to win group +390, to finish top two in group -150</li>
<li>The Czech Republic to win group +1150, to finish top two in group +200</li>
<li>Scotland to win group +1900, to finish top two in group +310</li>
</ul>
There are many betting options for soccer games including betting on the winner, a tie, a team to win or tie, over/under, correct score, both teams to score and the winning margin.
For this betting preview, we will be looking at who is likely to win Group D and finish second as the top two teams will advance past the group stage.
England (FIFA rank: 4) is a significant favorite in the group stage. It would be a pretty big upset if England didn&rsquo;t win the group. The team went 7-0-1 in qualifying with 37 goals scored and 6 goals allowed.
The team did lose to the Czech Republic 2-1 which could make its matchup a revenge game. Harry Kane led all players in the qualifying rounds of the Euro with 12 goals. Raheem Sterling added 8 goals.
Croatia (FIFA rank: 14) is the favorite to finish second. The team went 5-2-1 in qualifying in a group including&nbsp;Wales and Slovakia. In 2021, Croatia has faced off against some weaker competition such as&nbsp;Cyprus, Slovenia, Malta and Armenia. The results have been mixed.
The Czech Republic (FIFA rank: 40) went 5-0-3 in qualifying and is being considered a sleeper pick to finish second in the group. The team will need to figure out its goal-scoring with only 13 goals scored in 8 qualifying matches.
Scotland (FIFA rank: 44) went 5-0-5 in qualifying and faces a tough group to get out of. The team had a goal differential of -3 and allowed 19 goals.
Group D Picks: The safe bets seem to be England winning the group and Scotland finishing&nbsp;fourth. The real matchup is between Croatia and the Czech Republic to finish second.
Given the odds paying better for the Czech Republic, the value could be there for bettors with that country having a good shot of finishing second in Group D.
(Image by&nbsp;<a href="https://pixabay.com/users/jarmoluk-143740/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=488700">Michal Jarmoluk</a>&nbsp;from&nbsp;<a href="https://pixabay.com/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=488700">Pixabay</a>)

Euro 2020 Group D Betting Preview And Picks

The Taproot soft fork for Bitcoin (BTC) has locked in, as per Taproot.Watch, and is now set to be activated in November on block number 709,632.
What Happened:&nbsp;The threshold of more than 90% of all blocks signaling support for Taproot was crossed Sunday morning. This meant that at least 1,815 of 2,016 blocks within a 2-week difficulty period signaled support for the upgrade.
Taproot is expected to improve the privacy and fungibility of Bitcoin, alongside lowering transaction fees and incorporate efficiency improvements.
See Also: <a href="https://www.benzinga.com/money/how-to-buy-bitcoin/">How To Buy Bitcoin</a>
The soft fork will be the most significant upgrade to Bitcoin&rsquo;s blockchain since SegWit, a soft fork activated in 2017.
As part of Taproot, the existing elliptic curve digital signature algorithm of Bitcoin will be replaced with Schnorr signatures, considered to be more secure, privacy-oriented, and better-suited for multisignature transactions by proponents.
The 5-month period between the locking and the implementation of the actual upgrade allows miners the time to upgrade to the Bitcoin Core 0.21.1 software.
Price Action:&nbsp;Bitcoin traded 3.3% lower at $35,900.28 at press time on Sunday.
Read Next:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21360416/marathon-digital-to-begin-signaling-for-bitcoin-taproot-activation-heres-what-that-means">Marathon Digital To Begin Signaling For Bitcoin Taproot Activation: Here&#39;s What That Means</a>

Bitcoin Set For Biggest Upgrade In Years As Taproot Gets The 90% Mandate

<ul>
<li>Hedge fund Mudrick Capital lost 10% in just a few days amid a surge in&nbsp;AMC Entertainment Holdings Inc&#39;s&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>) stock price, the&nbsp;<a href="https://www.wsj.com/articles/amc-bet-by-hedge-fund-unravels-thanks-to-meme-stock-traders-11623431320?mod=hp_lead_pos5" target="_blank">Wall Street Journal</a>&nbsp;reported.</li>

<li>The fund is still up 12% year-to-date, while shares of AMC are up more than 2000% year-to-date.</li>

<li>Earlier this month, Mudrick Capital announced that it purchased $230.5 million of AMC shares directly from the company at $27.12 per share. The fund later<a href="https://www.benzinga.com/news/21/06/21376226/mudrick-capital-cashes-out-of-overvalued-amc-entertainment-investment-just-hours-after-buying-in-rep">&nbsp;sold&nbsp;them</a> at a profit.</li>

<li>Mudrick reportedly decided to cash out after it determined that AMC Entertainment&#39;s <a href="http://www.benzinga.com/news/21/06/21403655/missing-out-on-massive-amc-stock-surge-mudrick-capital-says-has-no-regrets-on-selling-nypost">shares are &quot;overvalued&quot;</a> and as it values businesses based on fundamentals.</li>

<li>The runaway spike&nbsp;occurred on June 2, when AMC shares rose as much as 127% to $72.62.</li>

<li>The losses for Jason Mudrick&#39;s fund&nbsp;primarily came&nbsp;from it selling&nbsp;AMC call options&nbsp;at $40 each, as per WSJ.</li>

<li>AMC&#39;s stock price blew past $40 on June 2, with an intraday high of $72.62.&nbsp;Call option prices soared amid frenzy trading and later cost the fund millions of losses. Mudrick decided to exit the AMC debt and derivative positions the next day in an internal meeting conducted on the evening of June 1, WSJ reported.</li>

<li>The fund made a 5% return on the debt and, after accounting for its options trade, the fund incurred a net loss of about 5.4% on AMC.</li>

<li>Mudrick had previously invested in AMC as it navigated a difficult period during the COVID-19 pandemic that forced the closure of its theatres.</li>

<li>Earlier this year, investors on Reddit&#39;s WallStreetBets form led a short squeeze in&nbsp;GameStop Corporation&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gme#NYSE">GME</a>), which caused short sellers to lose billions. AMC <a href="https://www.benzinga.com/news/21/06/21402359/amc-dizzying-rally-on-wednesday-took-companys-valuation-rocketing-past-rival-stonk-gamestop">overtook GameStop</a> in terms of market valuation earlier this month with a sudden surge.</li>

<li>Photo<a href="https://commons.wikimedia.org/wiki/File:AMC,_Theaters,_Plainville,_CT.jpg">&nbsp;via Wikimedia</a>.&nbsp;</li>
</ul>

Hedge Funds

AMC Stock Surge Caused 10% Loss For Mudrick Capital In Span Of Few Days: WSJ

<ul>
<li>Amazon.com, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) founder, Jeff Bezos&#39; Blue Origin, held&nbsp;a live auction on Saturday for a seat on its first spaceflight trip next month.</li>

<li>The live auction began at 1 p.m. EDT and lasted a few minutes. The bidding began at $4.8 million. The&nbsp;winning bid was that of $28 million<a href="https://www.youtube.com/watch?v=JUcQmETFmds">.</a>&nbsp;The name of the winner is expected to be disclosed in the coming weeks.<iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" frameborder="0" height="505" src="https://www.youtube.com/embed/JUcQmETFmds" width="650"></iframe></li>
</ul>
<ul>
<li>The auction kicked off on May 5 with sealed bids and continued till June 10.&nbsp;</li>

<li>According to Blue Origin, it got entries from more than 6,000 people from 143 countries.&nbsp;</li>

<li>The winner will then get one of the six seats on Blue Origin&#39;s first flight, which is currently set for July 20, and fly on the spacecraft with <a href="https://www.benzinga.com/news/21/06/21448828/jeff-bezos-will-travel-to-space-on-blue-origin-flight">Jeff Bezos</a><a href="http://www.benzinga.com/news/21/06/21448828/jeff-bezos-will-travel-to-space-on-blue-origin-flight"> and his brother</a> for 11 minutes. It isn&#39;t clear if the other three seats will be occupied.&nbsp;</li>

<li>The trip in the 60-foot-tall suborbital rocket will take the crew 62 miles (100 kilometers) above the Earth&#39;s surface.</li>

<li>The Blue Origin launch is set for Launch Site One in Texas.</li>

<li>Bezos&#39;s space exploration company&nbsp;competes with Richard Branson&#39;s&nbsp;Virgin Galactic Holdings Inc&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spce#NYSE">SPCE</a>)&nbsp;and Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) CEO Elon Musk&#39;s SpaceX.</li>

<li>The money raised from this auction will go towards Blue Origin&#39;s foundation, which the company says will contribute towards the development of life in space and inspire future generations to pursue careers in science.</li>

	&nbsp;
<li>&nbsp;</li>
</ul>
Photo courtesy of Blue Origin.

Travel

Tech

SPCE

Jeff Bezos' Blue Origin Auctions Seat On First Spaceflight For $28M

<img alt="Fintech Header" src="https://cdn2.hubspot.net/hub/2786381/hubfs/Fintech%20Header.png?upscale=true&amp;width=800&amp;upscale=true&amp;name=Fintech%20Header.png" />
<a href="https://www.benzinga.com/fintech/21/06/21484720/atom-finance-launches-white-labeled-data-experiences-partners-with-inter?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--7d34td2joZJNXk7Pb4Q1RM96gHIulTwg--sTASuhbIEiaAkm5Dx9RD-M_rHDrwo_0WiXP">Atom Finance Launches White-Labeled Data Experiences, Partners With Inter</a> 
Atom Finance, a modern financial knowledge platform, announced its first product integration partnership with Inter, a digital platform for banking, shopping, insurance, and investments.
<img src="https://cdn2.hubspot.net/hub/2786381/hubfs/Atom.png?upscale=true&amp;width=800&amp;upscale=true&amp;name=Atom.png" />
<a href="https://www.benzinga.com/fintech/21/06/21484846/public-launches-brand-campaign-focused-on-community-long-term-stability?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--7d34td2joZJNXk7Pb4Q1RM96gHIulTwg--sTASuhbIEiaAkm5Dx9RD-M_rHDrwo_0WiXP">Public Launches Brand Campaign Focused On Community, Long-Term Stability</a> 
In light of the commission-free trading revolution and speculative commentary on online forums like WallStreetBets, Public.com launched a new brand identity and campaign, honing in on proper portfolio building, wealth creation, and preservation.
<img src="https://cdn2.hubspot.net/hub/2786381/hubfs/app-social_feed_0.png?upscale=true&amp;width=800&amp;upscale=true&amp;name=app-social_feed_0.png" />
<a href="https://www.benzinga.com/fintech/21/06/21423204/fintech-spotlight-startup-infinite-sweeps-develops-ai-driven-option-orderflow-tool?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--7d34td2joZJNXk7Pb4Q1RM96gHIulTwg--sTASuhbIEiaAkm5Dx9RD-M_rHDrwo_0WiXP">Fintech Spotlight: Startup Infinite Sweeps Develops AI-Driven Option Orderflow Tool</a> 
In recognition of those disruptive innovators creating positive and diverse change within the financial services space, Benzinga spoke with John Michaelis, Arnav Pangasa, and Sohil Kollipara, founders at Infinite Sweeps.
<img src="https://cdn2.hubspot.net/hub/2786381/hubfs/cover_photo_28.png?upscale=true&amp;width=800&amp;upscale=true&amp;name=cover_photo_28.png" />
<a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21421965/professional-fighters-league-announces-first-mma-nfts?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--7d34td2joZJNXk7Pb4Q1RM96gHIulTwg--sTASuhbIEiaAkm5Dx9RD-M_rHDrwo_0WiXP">Professional Fighters League Announces First MMA NFTs</a> 
The Professional Fighters League (PFL), a fast-growing and innovative sports league, formally announced the first official digital collectibles partnership for an MMA organization.
<img src="https://cdn2.hubspot.net/hub/2786381/hubfs/copy_of_courtesy_photo_1_7_0_0.png?upscale=true&amp;width=800&amp;upscale=true&amp;name=copy_of_courtesy_photo_1_7_0_0.png" />
<a href="https://www.benzinga.com/news/earnings/21/06/21421807/moneylion-announces-q1-earnings-results-growth-expectations?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--7d34td2joZJNXk7Pb4Q1RM96gHIulTwg--sTASuhbIEiaAkm5Dx9RD-M_rHDrwo_0WiXP">MoneyLion Announces Q1 Earnings Results, Growth Expectations</a> 
In providing American&rsquo;s better access to modern mobile banking, investing, cash management, and credit building, MoneyLion&#39;s customer base grew 80% in the first quarter of 2021. Revenues also grew, amid a 204% increase in originations, to $188.7 million, compared to $62 million in the same period last year.
<img src="https://cdn2.hubspot.net/hub/2786381/hubfs/roarmoney_923a2aa5_0.jpeg?upscale=true&amp;width=800&amp;upscale=true&amp;name=roarmoney_923a2aa5_0.jpeg" />
<a href="https://www.benzinga.com/fintech/21/06/21401292/fintech-spotlight-yieldstreet-taps-100m-series-c-to-bolster-new-era-of-investing?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--7d34td2joZJNXk7Pb4Q1RM96gHIulTwg--sTASuhbIEiaAkm5Dx9RD-M_rHDrwo_0WiXP">Fintech Spotlight: Yieldstreet Taps $100M Series C To Bolster New Era Of Investing</a> 
Yieldstreet, a platform that enables millions of people to generate income from investments previously reserved for institutions and the ultrawealthy, raised $100 million in a Series C round led by Tarsadia Investments.
<img src="https://cdn2.hubspot.net/hub/2786381/hubfs/pexels-sevenstorm-juhaszimrus-443383_0.jpeg?upscale=true&amp;width=800&amp;upscale=true&amp;name=pexels-sevenstorm-juhaszimrus-443383_0.jpeg" />
<a href="https://www.benzinga.com/fintech/21/06/21381040/meet-tradestation-backed-aries-a-data-focused-broker-built-by-and-for-traders?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--7d34td2joZJNXk7Pb4Q1RM96gHIulTwg--sTASuhbIEiaAkm5Dx9RD-M_rHDrwo_0WiXP">Meet TradeStation-Backed Aries, A Data-Focused Broker Built By And For Traders</a> 
Aries, a retail-focused brokerage built by and for traders, is set to launch globally this summer.
In light of the company&rsquo;s rapid growth in popularity, Benzinga chatted with founder and CEO Reda Falih regarding motivations, products and timelines.
<img src="https://cdn2.hubspot.net/hub/2786381/hubfs/firmbee-com-spvhcbuki6e-unsplash.jpeg?upscale=true&amp;width=800&amp;upscale=true&amp;name=firmbee-com-spvhcbuki6e-unsplash.jpeg" />
<a href="https://www.benzinga.com/fintech/21/06/21382013/fintech-spotlight-how-tatatu-rewards-content-producers-consumers?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--7d34td2joZJNXk7Pb4Q1RM96gHIulTwg--sTASuhbIEiaAkm5Dx9RD-M_rHDrwo_0WiXP">Fintech Spotlight: How TaTaTu Rewards Content Producers, Consumers</a> 
TaTaTu, a new way for users to value and earn rewards for personal data, created the first sharing economy of data on its social media platform, available on desktop and mobile.
As part of the development, Benzinga chatted with CEO and founder Andrea Iervolino.
<img src="https://cdn2.hubspot.net/hub/2786381/hubfs/cover_photo_27.png?upscale=true&amp;width=800&amp;upscale=true&amp;name=cover_photo_27.png" />
<a href="https://www.benzinga.com/fintech/21/06/21378345/tradovate-offers-commission-free-access-to-new-futures-exchange-fairx?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--7d34td2joZJNXk7Pb4Q1RM96gHIulTwg--sTASuhbIEiaAkm5Dx9RD-M_rHDrwo_0WiXP">Tradovate Offers Commission-Free Access To New Futures Exchange, FairX</a> 
As part of a vision to change the futures industry through technology and pricing innovation, Tradovate announced it will be one of the first brokers to offer futures trading on FairX, a new CFTC-regulated futures exchange slated to launch this month.
<img src="https://cdn2.hubspot.net/hub/2786381/hubfs/pexels-photo-6801874_0.jpeg?upscale=true&amp;width=800&amp;upscale=true&amp;name=pexels-photo-6801874_0.jpeg" />
<a href="https://www.benzinga.com/general/sports/21/06/21480403/exclusive-how-floyd-mayweather-jr-grew-his-boxing-franchise-and-legacy-during-the-pandemic?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--7d34td2joZJNXk7Pb4Q1RM96gHIulTwg--sTASuhbIEiaAkm5Dx9RD-M_rHDrwo_0WiXP">EXCLUSIVE: How Floyd Mayweather Jr. Grew His Boxing Franchise And Legacy During The Pandemic</a> 
On June 6, YouTube star Logan Paul and professional boxer Floyd Joy Mayweather Jr. went head to head in an exhibition at the Hard Rock Stadium in Miami. The event lasted for eight rounds of 3 minutes each, and no official winner was read.
In light of the high-dollar exhibition round, Benzinga had the opportunity to sit down and speak with James Williams, CEO at Mayweather Boxing + Fitness, as well as actor and longtime Mayweather friend Cuba Gooding Jr. to talk about Mayweather&rsquo;s brand and vision to disrupt the fitness industry.
<img src="https://cdn2.hubspot.net/hub/2786381/hubfs/james_williams_image_-_crop_to_use_as_main_photo_698_459_82_int_c1-1.jpeg?upscale=true&amp;width=800&amp;upscale=true&amp;name=james_williams_image_-_crop_to_use_as_main_photo_698_459_82_int_c1-1.jpeg" />
<a href="https://www.benzinga.com/news/21/06/21504281/exclusive-psychedelics-pioneer-j-r-rahn-unpacks-decision-to-leave-mindmed-as-ceo?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--7d34td2joZJNXk7Pb4Q1RM96gHIulTwg--sTASuhbIEiaAkm5Dx9RD-M_rHDrwo_0WiXP">EXCLUSIVE: Psychedelics Pioneer J.R. Rahn Unpacks Decision To Leave MindMed As CEO</a> 
Mind Medicine (MindMed) Inc, a biotech company focused on the field of psychedelics, formally announced this week that J.R. Rahn, the company&rsquo;s co-founder and CEO, would step down.
Benzinga spoke with Rahn on what the transition means for MindMed, the industry and himself.
<img src="https://cdn2.hubspot.net/hub/2786381/hubfs/cover_photo_1_7.png?upscale=true&amp;width=800&amp;upscale=true&amp;name=cover_photo_1_7.png" />

Fintech news covering the emerging Financial Technology services sector

Fintech

Fintech Focus Roundup For June 13, 2021

&nbsp;
<ul>
<li>On Friday,&nbsp;Apple Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) confirmed a New York Times report that the Department of Justice (DOJ) sent a request in February 2018 and demanded metadata on 73 phone numbers and 36 email addresses,&nbsp;<a href="https://www.reuters.com/technology/apple-tightens-legal-request-rules-after-justice-department-targets-lawmakers-2021-06-11/" target="_blank">Reuters</a>&nbsp;reports.&nbsp;</li>

<li>Apple said it has tightened some of its rules for responding to legal requests after the DOJ during Donald Trump&#39;s presidency subpoenaed it for information on Democratic lawmakers.</li>

<li>The company said it has instituted a limit of 25 identifiers such as email addresses or phone numbers per legal request.</li>

<li>According to the report, Apple released only basic &quot;account subscriber information&quot; such as names, addresses, email addresses, and telephone numbers and connection logs and IP addresses in response to the DOJ request.</li>

<li>The company said that it limited the information it provided to metadata and account subscriber information and did not provide any content such as emails.</li>

<li>The inspector from the justice department,&nbsp;General Michael Horowitz, has said that &quot;he will investigate the department&#39;s efforts under Trump to seize the communications data of lawmakers and members of the news media.&quot;</li>

<li>On Thursday, the New York Times reported the DOJ had&nbsp;<a href="https://www.benzinga.com/government/21/06/21526928/trump-government-summoned-apple-to-investigate-information-leaks-reuters" target="_blank">subpoenaed&nbsp;</a>Apple for data from the accounts of at least two Democrats on the House of Representatives Intelligence Committee to investigate classified information leaks.&nbsp;</li>

<li>Apple has said that it received the subpoena from the Justice Department on Feb. 6, 2018, but it contained no information about who the investigation was targeting or why.&nbsp;</li>

<li>In a statement, Apple said that it believes similar requests were sent to other technology companies and internet service providers.</li>
	&nbsp;
</ul>
Read Next:&nbsp;<a href="https://www.benzinga.com/news/21/04/20475964/snapchat-risks-apples-wrath-with-attempts-at-skirting-new-privacy-rules-ft">Snapchat Risks Apple&#39;s Wrath With Attempts At Skirting New Privacy Rules: FT</a>
&nbsp;

Politics

Legal

Apple Says It Hardened Rules On Legal Requests After Trump Administration's Subpoena

-Sky News
<a href="https://news.sky.com/story/branson-plots-3bn-spac-merger-to-launch-virgin-orbit-onto-stock-market-12330845" title="https://news.sky.com/story/branson-plots-3bn-spac-merger-to-launch-virgin-orbit-onto-stock-market-12330845">https://news.sky.com/story/branson-plots-3bn-spac-merger-to-launch-virgin-orbit-onto-stock-market-12330845</a>

Rumors

NGCA

Richard Branson in Talks to Take Virgin Orbit Public Through Merger with SPAC NextGen Acquisition II Corp

Dogecoin (DOGE) co-creator Billy Markus shared his thoughts on Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) CEO Elon Musk and others&rsquo; efforts to advance and develop the meme coin.
What Happened: Musk had said in May that he was working with &ldquo;Doge devs to improve system transaction efficiency.&rdquo; He had termed it <a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21119489/elon-musk-working-with-dogecoin-devs-to-improve-system-transaction-efficiency" style="text-decoration-line:none">&ldquo;potentially promising&rdquo;</a> at the time.
On&nbsp;the development front, Markus told Benzinga that he was &ldquo;not super excited about people talking about doing things, only people actually doing things.&rdquo; He said he would see &ldquo;how it plays out.&rdquo;
See Also: <a href="https://www.benzinga.com/money/how-to-buy-dogecoin-doge/" style="text-decoration-line:none">How to Buy Dogecoin (DOGE)</a>
The Dogecoin co-creator made it clear that his comments were not a &ldquo;knock on elon or anyone in particular.&rdquo; He said this is just his general feeling about software advancement.
DOGE traded 4.59% higher at $0.308 at press time over 24 hours. The cryptocurrency is down 4.68% against both&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment/" style="text-decoration-line:none">Bitcoin</a> (BTC) and&nbsp;Ethereum (ETH).
BTC traded 4.7% lower at $35,531.15 at press time, while ETH traded 3.19% higher at $2,385.22.
Why It Matters: Musk also asked his followers on Twitter Inc&rsquo;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/twtr#NASDAQ">TWTR</a>) platform last month to <a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21269336/elon-musk-might-reconsider-his-stance-on-bitcoin-mining-asks-followers-to-help-dogecoin-de" style="text-decoration-line:none">submit ideas for DOGE development</a> on GitHub and Reddit.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21291152/elon-musks-starlink-can-help-scale-up-dogecoin-without-protocol-changes-proposes-researche" style="text-decoration-line:none">Elon Musk&#39;s Starlink Can Help Scale Up Dogecoin Without Protocol Changes, Proposes Researcher</a>
The Tesla CEO admitted in May that he does not have a similar role in Dogecoin and that his ability to &ldquo;<a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21290616/elon-musk-says-he-isnt-the-doge-ceo-ability-to-take-action-is-limited" style="text-decoration-line:none">take action is limited</a>.&rdquo;
Last month, <a href="https://www.benzinga.com/markets/cryptocurrency/21/02/19606989/what-is-cardano">Cardano</a> (ADA) creator and Ethereum co-creator Charles Hoskinson suggested a <a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21190100/elon-musk-gets-schooled-by-ethereum-co-founder-on-how-to-improve-dogecoin" style="text-decoration-line:none">plan of action to &ldquo;fix&rdquo; Dogecoin</a>.&nbsp;&nbsp;
Vitalik Buterin, another co-creator of Ethereum, though see&rsquo;s Musk&rsquo;s plans of <a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21250654/why-ethereum-co-founder-sees-elon-musks-plan-for-scaling-dogecoin-as-infeasible" style="text-decoration-line:none">scaling up DOGE as infeasible</a>.
Buterin said this month that he loves Dogecoin and said that a<a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21424614/vitalik-buterin-says-he-loves-doge-suggests-dogecoin-ethereum-collaboration-for-scalabilit" style="text-decoration-line:none"> Doge-to-Ethereum bridge</a> would be &ldquo;amazing.&rdquo;
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21485890/vitalik-buterin-is-a-dogecoin-hodler-says-meme-crypto-has-proved-one-of-best-investments" style="text-decoration-line:none">Vitalik Buterin Is A Dogecoin Hodler, Says Meme Crypto Has Proved One Of &#39;Best Investments&#39;</a>

Exclusives

Interview

TWTR

EXCLUSIVE: Dogecoin Co-Creator On Development Efforts Says 'No Knock On Elon,' Others But Actions Speak Louder Than Words

What Happened: Ken Moelis, billionaire investor and head of global investment bank Moelis &amp; Co (NYSE:&nbsp;MC) said he had&nbsp;been watching the cryptocurrency space carefully.
When asked whether he was considering a move into the space in an interview with <a href="https://www.bloomberg.com/news/articles/2021-06-08/moelis-likens-crypto-to-gold-rush-watches-for-opportunities?utm_medium=social&amp;utm_content=crypto&amp;utm_source=twitter&amp;utm_campaign=socialflow-organicflow-organic" style="color:#0563c1; text-decoration:underline">Bloomberg</a>, Moelis said, &ldquo;Maybe on the personal side, definitely on the business side, we are focused on having expertise and we do.&rdquo;
Moelis went on to say that &ldquo;It&rsquo;s a big market and there&rsquo;s a lot of capital in there, there&rsquo;s a lot of projects in the space&hellip;its like the Gold Rush of 1858.&rdquo;
According to him, Moelis is in the business of providing people with the &ldquo;picks and shovels&rdquo; and hence should know what people want&nbsp;and what tools they need to be successful.
For the moment, Moelis plans to watch the space and continue to learn, saying, &ldquo;I&rsquo;m trying to keep track of it, and stay up to speed with it and I wouldn&rsquo;t say I&rsquo;m a total believer or a total non-believer.&rdquo;
Read also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21488769/berkshire-hathaway-invests-500m-in-brazilian-digital-bank-nubank">Berkshire Hathaway Invests $500M In Brazilian Digital Bank Nubank</a>
The investment banker also commented on the meme-stock craze, where retail investors have benefited immensely from holding positions in stocks like GameStop Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gme#NYSE">GME</a>) and AMC Entertainment Holdings Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>).
&quot;They&#39;re just having fun - I think 70 to 80% of this is fun,&quot; he said. &quot;When you go to a casino, the most boisterous, loudest craps table is always the one where everyone runs over because someone has made their point, they&#39;ve predicted something.&quot;
Price Action:&nbsp;Moelis &amp; Company stock closed at $54.64, 1.22%.
Bitcoin gained 0.55% during the day and stood at&nbsp;$36,855&nbsp;at press time.
The entire crypto market lost 2.4% over the last 24-hours was at&nbsp;$1.54 trillion&nbsp;as of press time.

Management

Billionaire Ken Moelis Is Watching The Crypto Space, Compares It To Gold Rush Of 1848

The <a href="https://e3expo.com/">E3 Expo</a> is one of the largest video game conference held every year. This year&#39;s event will be held virtually and viewers can tune in for free to get presentations from some of the largest gaming companies and also get gameplay demo videos.
The event is titled &quot;Online. Interactive. Worldwide. Game On.&quot; for 2021.&nbsp;
Microsoft: One of the largest gaming companies with its Xbox console and gaming divisions, Microsoft Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) is among the largest E3 presenters. Viewers are looking forward to seeing Microsoft present with Bethesda, which it&nbsp;acquired, together for the first time.
Microsoft could unveil more details on the Xbox Game Pass and the reasons why gamers should be paying monthly for exclusive games from the company.
Bethesda could highlight its lineup in The Elder Scrolls&nbsp;franchise and could also discuss its upcoming space,&nbsp;the RPG Starfield,&nbsp;one of its first new intellectual properties in years.
After being delayed from a release along with the Xbox Series X, Halo Infinite&nbsp;has been delayed multiple times. The game could be a highlight from Microsoft at the event.
Nintendo: One of the biggest companies to watch at E3 is Nintendo Co., Ltd. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/ntdoy#OTC">NTDOY</a>). The company could show more gameplay from upcoming highly anticipated games such as&nbsp;Metroid Prime 4,&nbsp;Splatoon 3,&nbsp;Pokemon Brilliant Diamond,&nbsp;Pokemon Shining Pearl&nbsp;and Pokemon Legends: Arceus.
Viewers will also be hoping for any news or gameplay on the highly anticipated Breath of the Wild&nbsp;sequel in the Zelda series.
Nintendo could also introduce the Nintendo Switch Pro gaming console. The new console is rumored to have a larger OLED screen and would be the next version of the bestselling console.
Ubisoft: Gaming studio Ubi Soft Entertainment (OTC: <a class="ticker" href="https://www.benzinga.com/stock/ubsfy#OTC">UBSFY</a>) will hold a panel at E3 that could include updates on several upcoming games. The footage could be shown from games such as Far Cry 6,&nbsp;Rainbow Six: Quarantine&nbsp;and Assassin&rsquo;s Creed Valhalla.&nbsp;The company could also surprise with some new announcements or gameplay from games for the first time.
Related Link: <a href="https://www.benzinga.com/news/21/02/19884348/pokemon-announces-highly-anticipated-diamond-and-pearl-remakes-why-investors-should-watch-nintendo-s">Pokemon Announces Highly Anticipated Diamong And Pearl Remakes: Why Investors Should Watch Nintendo&#39;s Stock&nbsp;</a>
Capcom: Gaming studio Capcom ADR&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/ccoey#OTC">CCOEY</a>) is presenting at E3 and could show off details and gameplay from some of the most well-known gaming franchises like Monster Hunter and Resident Evil.
Viewers could also get a look at Pragmata, a sci-fi game expected to be released in 2023. Capcom had hinted earlier that gameplay could be coming soon for Pragmata and E3 could be the perfect place to make its debut.
Galaxy Digital: Blockchain and digital asset investment company Galaxy Digital Holdings Ltd&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/brphf#OTC">BRPHF</a>) is a stock to watch with its ties to a company that could get some new interest because of&nbsp;the E3 event.
Mythical Games is a gaming studio using playable <a href="https://www.benzinga.com/money/what-is-a-non-fungible-token-nft/">non-fungible tokens</a>. The company&rsquo;s Blankos Block Party&nbsp;game was called a &ldquo;Fall Guys meets Roblox meets Funko Pop&rdquo; by <a href="https://techcrunch.com/2021/06/09/mythical-games-raises-75m-to-build-an-nft-game-engine/">TechCrunch </a>recently.
The game allows users to buy and sell items through a marketplace living on a private blockchain. The items can&rsquo;t be re-sold on public marketplaces, which could keep more revenue in-house for Mythical Games.
An open beta for Blankos Block Party&nbsp;has seen players hold more than&nbsp;100,000 NFT in the open-world playable NFT game.
The social gaming aspects of the game along with the interest in NFTs could make this a future hit. The company recently <a href="https://venturebeat.com/2021/06/09/mythical-games-raises-75-million-for-blankos-block-party-game-and-playable-nfts/">raised </a>$75 million in funding with investments from Gary Vaynerchuk&rsquo;s VaynerFund and existing investor Galaxy Digital.
Mythical Games will present on Monday,&nbsp;June 14 and will also have a NFT Twitch drop.
Others to Watch: Other companies presenting include Square Enix (OTC: <a class="ticker" href="https://www.benzinga.com/stock/sqnny#OTC">SQNNY</a>), Sony Group&nbsp;Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sony#NYSE">SONY</a>), Sega Sammy Holdings Inc (OTC: <a class="ticker" href="https://www.benzinga.com/stock/sgamy#OTC">SGAMY</a>), Take-Two Interactive Software (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttwo#NASDAQ">TTWO</a>), Verizon Communications Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vz#NYSE">VZ</a>), NetEase Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntes#NASDAQ">NTES</a>) and SK Telecom Co Ltd (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/skm#NYSE">SKM</a>).
(Photo by <a href="https://unsplash.com/@jeshoots?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">JESHOOTS.COM</a> on <a href="https://unsplash.com/s/photos/video-games?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>)
<iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" frameborder="0" height="315" src="https://www.youtube.com/embed/78hw4-19bk8" width="560"></iframe>

Penny Stocks

Events

Movers

BRPHF

CCOEY

MSFT

NTDOY

NTES

SGAMY

Sony Group Corporation American Depositary Shares

SONY

SQNNY

TTWO

UBSFY

E3 2021: 12 Stocks To Watch For The Year's Biggest Video Game Event

&ldquo;Cannibble = Cannabis + Nibble&rdquo; says Israeli food technology startup <a href="https://cannibble.world">Cannibble Foodtech LTD</a>, a developer &amp; manufacturer of powder mix food, beverages, nutritional supplements, and spices infused with active cannabinoids or hemp seeds. Cannibble was founded in Aug 2018 by a group of individuals with experience in the fields of food development/sales and cannabis expertise.
&ldquo;Our team has more than 30 years of experience in developing and marketing edibles worldwide. Our mission is to create fun powder food products enhanced with cannabis. We aim to become a leader in the cannabis edible markets and to create a new &lsquo;Canna-food&rsquo; segment for recreational markets.&rdquo;
Having developed proprietary formulas to enhance powder-based edibles with active Cannabinoids, Cannibble has already raised approximately $2.5M USD for the development and implementation of its product line. A unique THC line of products is expected to be launched in Canada during Q2-2021.
The company completed the development of three families of revolutionary formulations for new premixed powder food products infused with cannabis and hemp-derived ingredients. These families of products cover the entire spectrum of cannabis edibles consumption today with Hemp Seeds, Oils, Protein and flower, CBD-based products, and THC-based products for the adults&rsquo; recreational market according to local regulations and policies.&nbsp;&nbsp;
&ldquo;Our leading house brand is called &lsquo;The Pelicann&rsquo; and presents the following families of products, all available to consumers today in several locations in the USA and soon in Canada. The products offer a full range of cannabis-infused products.&rdquo;
<h2>New Frontiers of Cannabis</h2>
Cannibble is additionally finishing up a crowd-funding investment round for its Pelicann product line up through FrontFundr <a href="https://www.frontfundr.com/cannibble">here</a>. The range of products includes:&nbsp;
<ul>
<li>Powders for making shakes with CBD, THC, or hemp in both standard and sports targeted protein options.</li>
<li>Mixes for baked goods with CBD, THC, or hemp.</li>
<li>Pure or blended spice mixes available with CBD or THC.</li>
<li>And microwave instant popcorn mixes available with CBD or THC.</li>
</ul>
The Cannibble edibles containing CBD are mainly for the wellness and health markets while those containing THC are for adults&#39; recreational use. The hemp seeds (which are derived as seed oils, protein and flower) are products that are most popular among consumers as a natural health ingredient.
In Benzinga&rsquo;s own home state of Michigan, growth in edibles sales have <a href="https://mjbizdaily.com/edibles-outperform-cannabis-industry-growth-in-2020-on-covid-spurred-sales-surge/">outperformed growth in regular cannabis sales for 2020</a> and shows no signs of stopping their current growth trend.

Cannabis

Food-Tech Startup Innovates in Rapidly Growing Edible Cannabis Market

<h3>GAINERS:</h3>
<ul>
<li><a href="https://quotes.benzinga.com/quote/CURR" target="_blank">CURE Pharmaceutical Hldg</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/curr#OTC">CURR</a>) shares closed up 12.33% at $0.82</li>
<li><a href="https://quotes.benzinga.com/quote/PMD" target="_blank">Psychemedics</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmd#NASDAQ">PMD</a>) shares closed up 11.9% at $8.37</li>
<li><a href="https://quotes.benzinga.com/quote/GENE" target="_blank">Genetic Technologies</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gene#NASDAQ">GENE</a>) shares closed up 9.13% at $4.54</li>
<li><a href="https://quotes.benzinga.com/quote/NINE" target="_blank">Nine Energy Service</a>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nine#NYSE">NINE</a>) shares closed up 7.86% at $2.47</li>
<li><a href="https://quotes.benzinga.com/quote/CNGGF" target="_blank">Cann Gr</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cnggf#OTC">CNGGF</a>) shares closed up 7.76% at $0.32</li>
<li><a href="https://quotes.benzinga.com/quote/INLB" target="_blank">Item 9 Labs</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/inlb#OTC">INLB</a>) shares closed up 7.74% at $3.48</li>
<li><a href="https://quotes.benzinga.com/quote/BMMJ" target="_blank">Body and Mind</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/bmmj#OTC">BMMJ</a>) shares closed up 7% at $0.39</li>
<li><a href="https://quotes.benzinga.com/quote/GRIN" target="_blank">Grindrod Shipping Hldgs</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grin#NASDAQ">GRIN</a>) shares closed up 5.98% at $10.45</li>
<li><a href="https://quotes.benzinga.com/quote/HERTF" target="_blank">Heritage Cannabis Holding</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/hertf#OTC">HERTF</a>) shares closed up 5.56% at $0.10</li>
<li><a href="https://quotes.benzinga.com/quote/IVITF" target="_blank">Invictus MD Strategies</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/ivitf#OTC">IVITF</a>) shares closed up 4.8% at $0.05</li>
<li><a href="https://quotes.benzinga.com/quote/MBII" target="_blank">Marrone Bio Innovations</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mbii#NASDAQ">MBII</a>) shares closed up 4.44% at $1.88</li>
<li><a href="https://quotes.benzinga.com/quote/ZYNE" target="_blank">Zynerba Pharmaceuticals</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zyne#NASDAQ">ZYNE</a>) shares closed up 4.06% at $5.64</li>
</ul>
<h4>LOSERS:</h4>
<ul>
<li><a href="https://quotes.benzinga.com/quote/CBWTF" target="_blank">Auxly Cannabis Group</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cbwtf#OTC">CBWTF</a>) shares closed down 9.22% at $0.21</li>
<li><a href="https://quotes.benzinga.com/quote/CNVCF" target="_blank">BioHarvest Sciences</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cnvcf#OTC">CNVCF</a>) shares closed down 7.8% at $0.23</li>
<li><a href="https://quotes.benzinga.com/quote/CVSI" target="_blank">CV Sciences</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cvsi#OTC">CVSI</a>) shares closed down 5.51% at $0.44</li>
<li><a href="https://quotes.benzinga.com/quote/CNPOF" target="_blank">RIV Capital</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cnpof#OTC">CNPOF</a>) shares closed down 4.86% at $1.31</li>
<li><a href="https://quotes.benzinga.com/quote/TGODF" target="_blank">Green Organic Dutchman</a>&nbsp;(OTC:TGOFG) shares closed down 2.84% at $0.31</li>
</ul>
<a href="https://www.benzinga.com/cannabis/stocks/">Check out a full list of cannabis stock movers in real time following this link.</a>
Lead image by Ilona Szentivanyi. Copyright: Benzinga.

BMMJ

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNGGF

CNPOF

CNVCF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

GENE

Grindrod Shipping Holdings Ltd Ordinary Shares

GRIN

HERTF

INLB

IVITF

MBII

NINE

ZYNE

Cannabis Stock Gainers And Losers From June 11, 2021

On <a href="https://www.cnbc.com/video/2021/06/11/buy-mgm-askhalftime.html">CNBC&#39;s &quot;Fast Money Halftime Report,&quot;</a> Stephen Weiss said he owns United Airlines Holdings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ual#NASDAQ">UAL</a>) and he believes it&#39;s a buy. He still sees it as a recovery play and he thinks margins are going to be strong.
Procter &amp; Gamble Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pg#NYSE">PG</a>) is a low volatility part of Shannon Saccocia&#39;s portfolio. It has a huge international footprint so it&#39;s a great way to get exposure to Europe and the emerging markets.
Jim Lebenthal still likes Boeing Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ba#NYSE">BA</a>). He is optimistic because of rumors about new orders from United Airlines and Qatar Airlines.
Degas Wright said MGM Resorts International (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mgm#NYSE">MGM</a>) is definitely a buy. One-half of all the beds in Las Vegas belongs to MGM so it&#39;s a reopen stock, said Wright. There is also some growth potential as more states could allow online gambling.

'Halftime Report' Traders Weigh In On United Airlines, Boeing And More

ALAC

Alberton Acquisition Corporation Receives NASDAQ Notice On Late Filing Of Its Form 10-Q

IPOs

Biomea Fusion Shares Open For Trade At $20; IPO Priced At $17/Share

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs April 20)

<ul>
	<li>Alexion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/ALXN#NASDAQ">ALXN</a>)</li>
	<li>AtriCure, Inc. (NASDAQ:<a class="ticker" href="/stock/ATRC#NASDAQ">ATRC</a>)</li>
	<li>BioNTech SE (NASDAQ:<a class="ticker" href="/stock/BNTX#NASDAQ">BNTX</a>)</li>
	<li>China Biologic Products Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/CBPO#NASDAQ">CBPO</a>) (announced completion of going private transaction)</li>
	<li>Dicerna Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/DRNA#NASDAQ">DRNA</a>)</li>
	<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="/stock/IART#NASDAQ">IART</a>)</li>
	<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="/stock/MGNX#NASDAQ">MGNX</a>)</li>
	<li>Medtronic plc (NYSE:<a class="ticker" href="/stock/MDT#NYSE">MDT</a>)</li>
	<li>United Therapeutics Corporation (NASDAQ:<a class="ticker" href="/stock/UTHR#NASDAQ">UTHR</a>)</li>
	<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="/stock/WST#NYSE">WST</a>)</li>
	<li>Zimmer Biomet Holdings, Inc. (NYSE:<a class="ticker" href="/stock/ZBH#NYSE">ZBH</a>) (reacted to FDA 510(k) clearance of the Rosa Partial Knee System for robotically-assisted partial knee replacement surgeries)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows April 20)

<ul>
	<li>4D Molecular Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/FDMT#NASDAQ">FDMT</a>)</li>
	<li>ADC Therapeutics SA (NYSE:<a class="ticker" href="/stock/ADCT#NYSE">ADCT</a>)</li>
	<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="/stock/ADMA#NASDAQ">ADMA</a>)</li>
	<li>Agile Therapeutics, Inc. (AGRX)</li>
	<li>Akoya Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/AKYA#NASDAQ">AKYA</a>) (IPOed Friday)</li>
	<li>Allena Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/ALNA#NASDAQ">ALNA</a>)</li>
	<li>Angion Biomedica Corp. (NASDAQ:<a class="ticker" href="/stock/ANGN#NASDAQ">ANGN</a>)</li>
	<li>Applied Genetic Technologies Corporation (NASDAQ:<a class="ticker" href="/stock/AGTC#NASDAQ">AGTC</a>)</li>
	<li>Assembly Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/ASMB#NASDAQ">ASMB</a>)</li>
	<li>Aurinia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/AUPH#NASDAQ">AUPH</a>)</li>
	<li>Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/AXSM#NASDAQ">AXSM</a>)</li>
	<li>Bellerophon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/BLPH#NASDAQ">BLPH</a>)</li>
	<li>Biomea Fusion, Inc. (NASDAQ:<a class="ticker" href="/stock/BMEA#NASDAQ">BMEA</a>) (IPOed Friday)</li>
	<li>Biomerica, Inc. (NASDAQ:<a class="ticker" href="/stock/BMRA#NASDAQ">BMRA</a>)</li>
	<li>Brainstorm Cell Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/BCLI#NASDAQ">BCLI</a>)</li>
	<li>BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="/stock/BCTX#NASDAQ">BCTX</a>)</li>
	<li>Calithera Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/CALA#NASDAQ">CALA</a>)</li>
	<li>Celyad Oncology SA (NASDAQ:<a class="ticker" href="/stock/CYAD#NASDAQ">CYAD</a>)</li>
	<li>Checkmate Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CMPI#NASDAQ">CMPI</a>)</li>
	<li>ChemoCentryx, Inc. (NASDAQ:<a class="ticker" href="/stock/CCXI#NASDAQ">CCXI</a>)</li>
	<li>Concert Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CNCE#NASDAQ">CNCE</a>)</li>
	<li>ContraFect Corporation (NASDAQ:<a class="ticker" href="/stock/CFRX#NASDAQ">CFRX</a>)</li>
	<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>) (Sell-side began initiating coverage following IPO quiet period expiry)</li>
	<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="/stock/EBS#NYSE">EBS</a>)</li>
	<li>Enveric Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/ENVB#NASDAQ">ENVB</a>)</li>
	<li>Evofem Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/EVFM#NASDAQ">EVFM</a>)</li>
	<li>Finch Therapeutics Group, Inc. (NASDAQ:<a class="ticker" href="/stock/FNCH#NASDAQ">FNCH</a>)</li>
	<li>Foghorn Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/FHTX#NASDAQ">FHTX</a>)</li>
	<li>Galera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/GRTX#NASDAQ">GRTX</a>)</li>
	<li>Gracell Biotechnologies Inc. (NASDAQ:<a class="ticker" href="/stock/GRCL#NASDAQ">GRCL</a>)</li>
	<li>Fusion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/FUSN#NASDAQ">FUSN</a>)</li>
	<li>Homology Medicines, Inc. (NASDAQ:<a class="ticker" href="/stock/FIXX#NASDAQ">FIXX</a>)</li>
	<li>Idera Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/IDRA#NASDAQ">IDRA</a>)</li>
	<li>Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/IKT#NASDAQ">IKT</a>)</li>
	<li>InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/INM#NASDAQ">INM</a>)</li>
	<li>Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/KPTI#NASDAQ">KPTI</a>)</li>
	<li>Kronos Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/KRON#NASDAQ">KRON</a>)</li>
	<li>Lixte Biotechnology Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/LIXT#NASDAQ">LIXT</a>)</li>
	<li>Lucira Health, Inc. (NASDAQ:<a class="ticker" href="/stock/LHDX#NASDAQ">LHDX</a>)</li>
	<li>MediciNova, Inc. (NASDAQ:<a class="ticker" href="/stock/MNOV#NASDAQ">MNOV</a>)</li>
	<li>Metacrine, Inc. (NASDAQ:<a class="ticker" href="/stock/MTCR#NASDAQ">MTCR</a>)</li>
	<li>Millendo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/MLND#NASDAQ">MLND</a>)</li>
	<li>NeuBase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/NBSE#NASDAQ">NBSE</a>)</li>
	<li>NuCana plc (NASDAQ:<a class="ticker" href="/stock/NCNA#NASDAQ">NCNA</a>)</li>
	<li>OraSure Technologies, Inc. (NASDAQ:<a class="ticker" href="/stock/OSUR#NASDAQ">OSUR</a>)</li>
	<li>Pharvaris B.V. (NASDAQ:<a class="ticker" href="/stock/PHVS#NASDAQ">PHVS</a>)</li>
	<li>Pulmatrix, Inc. PULM)</li>
	<li>Sigilon Therapeutics, Inc (NASDAQ:<a class="ticker" href="/stock/SGTX#NASDAQ">SGTX</a>)</li>
	<li>Soleno Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SLNO#NASDAQ">SLNO</a>)</li>
	<li>Stealth BioTherapeutics Corp (NASDAQ:<a class="ticker" href="/stock/MITO#NASDAQ">MITO</a>)</li>
	<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="/stock/UPC#NASDAQ">UPC</a>)</li>
	<li>Vaxcyte Inc (NASDAQ:<a class="ticker" href="/stock/PCVX#NASDAQ">PCVX</a>)</li>
	<li>VectivBio Holding AG (NASDAQ:<a class="ticker" href="/stock/VECT#NASDAQ">VECT</a>)</li>
	<li>Viveve Medical, Inc. (NASDAQ:<a class="ticker" href="/stock/VIVE#NASDAQ">VIVE</a>)</li>
	<li>Vyne Therapeutics Inc (NASDAQ:<a class="ticker" href="/stock/VYNE#NASDAQ">VYNE</a>)</li>
	<li>Zymeworks Inc. (NYSE:<a class="ticker" href="/stock/ZYME#NYSE">ZYME</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Lilly Announces Presentation of Positive Phase 1/2 Study of Selpercatinib In RET fusion-positive Solid Tumors</h3>

Eli Lilly and Company (NYSE:<a class="ticker" href="/stock/LLY#NYSE">LLY</a>) announced that it presented at the 2021 American Association for Cancer Research Annual Meeting data from the Phase 1/2 trial showing treatment with selpercatinib demonstrated encouraging antitumor activity and safety across RET fusion-positive advanced solid tumors beyond lung and thyroid cancers, including multiple treatment-refractory gastrointestinal malignancies.

The company noted a confirmed objective response rate of 47%, with responses observed in nine unique cancer types. Median duration of response was not reached at 13 months, with 11 of 15 responses ongoing, it added. The company also said safety was consistent with the known profile of selpercatinib.

<h3>Moderna Strikes Deal to Supply Israel Variant-specific COVID Vaccine In 2022</h3>

Moderna, Inc. (NASDAQ:<a class="ticker" href="/stock/MRNA#NASDAQ">MRNA</a>) announced a new supply agreement, with Israel, under which Israel also retains an option to purchase doses of one of Moderna&#39;s variant-specific vaccine candidates in 2022, subject to regulatory approval.

This follows two earlier agreements between Israel and Moderna to supply a total of 10 million doses of the COVID-19 Vaccine. The Israeli Ministry of Health authorized COVID-19 Vaccine Moderna for use on Jan.&nbsp;4.

<h3>Lumos Announces Retirement of CFO, Names Insider to the Role</h3>

Lumos Pharma, Inc. (NASDAQ:<a class="ticker" href="/stock/LUMO#NASDAQ">LUMO</a>) said chief financial officer Carl Langren, who has been with the company for 40 years, has announced his plans to retire effective as of July 4. Langren has been serving in the current role since November&nbsp;2019.

Lori Lawley, currently SVP, Finance and Corporate Controller, will succeed Langren as CFO. The company also announced the appointment of Eddie Varnado as VP, Finance and Corporate Controller.

<h3>Evelo Presents Positive Data for Phase 1b Study of Atopic Dermatitis Drug</h3>

Evelo Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/EVLO#NASDAQ">EVLO</a>) presented full clinical data from the Phase 1b clinical trial cohort evaluating EDP1815 for the treatment of mild and moderate atopic dermatitis in a poster presentation at the International Society of Atopic Dermatitis. The full results reinforce the data released on January 20, demonstrating that treatment with EDP1815 resulted in clinically meaningful improvements in both patient- and physician-reported outcomes, the company said.

The stock was up 1.48% at $11 in after-hours trading.

<h3>Trevena Says Its Investigational Asset Included In Global Study For COVID-19 Treatment</h3>

Trevena, Inc. (NASDAQ:<a class="ticker" href="/stock/TRVNA#NASDAQ">TRVNA</a>) said its TRV027 has been selected for inclusion in an international, multi-site, adaptive, Phase 2-Phase 3 trial in COVID-19 patients.

The stock was up 4.71% to $1.78 in premarket trading Wednesday.

<h3>Humanigen Announces Pharma Industry Veteran Adrian Kilcoyne as Chief Medical Officer </h3>

Humanigen, Inc. (NASDAQ:<a class="ticker" href="/stock/HGEN#NASDAQ">HGEN</a>), which is evaluating its lead drug lenzilumab for cytokine storm associated with COVID-19, said it has appointed Adrian Kilcoyne to the newly-created role of chief medical officer, effective immediately, reporting to Cameron Durrant, CEO of Humanigen.

He recently served as VP of Oncology Global Medical Affairs, Head of Evidence Generation and External Alliances, at AstraZeneca plc. (NASDAQ:<a class="ticker" href="/stock/AZN#NASDAQ">AZN</a>).

In premarket trading Wednesday, <a href="https://www.benzinga.com/general/biotech/21/03/20390403/humanigen-rallies-54-a-technical-analysis"> Humanigen shares </a> gained 1.18% to $13.70.

<h3>Applied DNA Pre-announces Above-consensus Q2 Revenues </h3>

Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="/stock/APDN#NASDAQ">APDN</a>) announced preliminary estimated second-quarter revenues in the range of $2.5 million to $2.7 million, up from $1.6 million in the first quarter and $552,000 in the year-ago quarter. Analysts, on average, estimate, revenues of $2.41 million.

The company attributed the sequential growth, principally to demand for safeCircle, its pooled COVID-19 surveillance testing program, and from sales of its Linea COVID-19 Assay Kit.

The company also said it&#39;s currently debt free.

<h3>Earnings </h3>

Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="/stock/ISRG#NASDAQ">ISRG</a>) said its first-quarter revenues climbed 18% year-over-year to $1.29 billion, and the non-GAAP net income per share climbed from $2.70 to $3.52, ahead of the $2.63 per share consensus.

The stock rose 3.81% to $842.02 in after-hours trading.

Roche Holding AG (OTC:<a class="ticker" href="/stock/RHHBY#OTC">RHHBY</a>) reported group sales of 14.93 billion francs ($16.26 billion) for the first quarter, down 1% but up 3% on a constant exchange rate. Sales of its Pharmaceutical business declined in all geographies, and the weakness was offset by a 50% increase in sales of its <a href="https://www.benzinga.com/general/biotech/21/03/20160023/roche-boosts-diagnostics-portfolio-with-1-8b-bet-on-covid-19-test-manufacturer-genmark">diagnostics business. </a> The company confirmed its outlook for 2021.

Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="/stock/EW#NYSE">EW</a>) said its first-quarter sales climbed 8% to $1.2 billion and EPS came in at 54 cents, exceeding the 47-cent per-share consensus estimate. The company raised its adjusted EPS guidance for 2021.

The stock added 3.76% to $93 in after-hours trading.

Related Link: <a href=" https://www.benzinga.com/general/biotech/21/04/20405937/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates </a>

Biotech

Earnings

Guidance

Health Care

Pre-Market Outlook

The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings

Piper Sandler analyst Joseph Catanzaro initiates coverage on Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Overweight rating and announces Price Target of $27.

Price Target

Initiation

Analyst Ratings

Piper Sandler Initiates Coverage On Biomea Fusion with Overweight Rating, Announces Price Target of $27

JP Morgan analyst Gavin Scott initiates coverage on Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Overweight rating and announces Price Target of $26.

JP Morgan Initiates Coverage On Biomea Fusion with Overweight Rating, Announces Price Target of $26

Jefferies analyst Eun Yang initiates coverage on Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Buy rating and announces Price Target of $26.

Jefferies Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $26

Upgrades

Downgrades

Intraday Update

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021

Offerings

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts

Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) reported quarterly losses of $(0.49) per share. This is a 880 percent decrease over losses of $(0.05) per share from the same period last year.

Biomea Fusion Q1 EPS $(0.49) Down From $(0.05) YoY

ABCL

ACHL

ACHV

ADCT

ADMA

ADMS

AFIB

AGTC

AKBA

AKUS

AKYA

ALGS

ALNA

ALXN

AMGN

ANGN

APDN

APLS

APPF

APRE

APTX

APYX

AQST

ARCT

ASMB

ATNX

ATRC

ATVI

AUPH

AVDL

AVEO

AVIR

AVRO

AVXL

AXDX

AXSM

BCEL

BCLI

BCTX

BDSI

BEAM

BEEM

BHVN

BIOC

BLFS

BLNK

BLPH

BMEA

BMRA

BNGO

BNTX

BPTH

BTAI

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-03
REV		(EXPECTED)2021-08-03

Q1 2021		Est.		Actual		Surprise
EPS				-0.490
REV				0

Recent Quotes

Earnings

Analyst Ratings

Related Companies

Biomea Fusion Frequently Asked Questions

How do I buy Biomea Fusion (BMEA) stock?

Who are Biomea Fusion's (BMEA) competitors?

What is the target price for Biomea Fusion (BMEA) stock?

Current Stock Price for Biomea Fusion (BMEA)?

Does Biomea Fusion (BMEA) pay a dividend?

When is Biomea Fusion (NASDAQ:BMEA) reporting earnings?

Is Biomea Fusion (BMEA) going to split?

What sector and industry does Biomea Fusion (BMEA) operate in?